Long-term survey of IM-treated CML patients confirms preferential acquisition of unbalanced ACA in patients with the b3a2 fusion type of p210BCR-ABL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.